Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Luxturna Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy CS2026D0064Q

    Luxturna (Voretigene Neparvovec-Rzyl)

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy CS2026D0064Q alerts

    Get alerted when Policy CS2026D0064Q changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This UnitedHealthcare Community Plan Medical Benefit Drug Policy governs prior authorization and medical-necessity coverage for Luxturna, a gene therapy for patients with confirmed biallelic RPE65 mutation-associated inherited retinal dystrophy, subject to state-specific policy exceptions and applicable benefit requirements.

    Policy Summary
    PayerUnitedHealthcare
    PolicyLuxturna (Voretigene Neparvovec-Rzyl)
    Policy CodePolicy CS2026D0064Q
    Change TypeSupporting-information update
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization establishing every applicable Luxturna coverage criterion.
    SourceLink
    POLICY UPDATE CHANGES

    The Background, Clinical Evidence, and References sections were updated to reflect the most current information.

    The prior policy version CS2026D0064P was archived.

    1/lifetime/eyeMaximum treatment frequency
    45 daysMaximum authorization duration
    >100 µmMinimum retinal thickness
    Biallelic RPE65

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Required genetic association
    J3398Luxturna HCPCS code
    6Excluded states

    Coverage Criteria

    Initial Luxturna treatment

    Covered when ALL of the following are met:

    Initial Luxturna therapy

    • Patient and disease criteria

      • Age: Patient is greater than 12 months of age.> 12 months
      • Diagnosis: Patient has a confirmed biallelic RPE65 mutation-associated retinal dystrophy, such as Leber congenital amaurosis, retinitis pigmentosa, or early-onset severe retinal dystrophy.
      • Genetic confirmation: Genetic testing documents biallelic mutations of the RPE65 gene.Biallelic RPE65 mutations
      • Retinal viability: Optical coherence tomography confirms sufficient viable retinal cells, defined as an area of retina within the posterior pole with thickness greater than 100 µm.> 100 µm posterior-pole thickness
    • Administration and authorization criteria

      • Qualified provider: Luxturna is prescribed and administered by an ophthalmologist or retinal surgeon with experience providing subretinal injections.
      • No prior treatment in intended eye: The patient has not previously received Luxturna treatment in the intended eye.
      • Inpatient admission restriction: The provider does not request a planned inpatient admission for the sole purpose of administering Luxturna.
      • Treatment and authorization limits: Authorization is requested for no more than one treatment per lifetime per eye and for no longer than 45 days from approval.1 treatment per lifetime per eye; authorization no longer than 45 days

    This policy does not apply in Florida, Indiana, Kansas, Ohio, Texas, or Virginia. Providers should refer to the applicable state-specific Medicaid policy, guideline, or manual for coverage requirements in those states.

    A planned inpatient admission requested solely for administration of Luxturna is excluded from the covered criteria.

    Coding and Clinical Parameters

    HCPCS CodeHCPCS
    J3398Injection, voretigene neparvovec-rzyl, 1 billion vector genomes
    Diagnosis CodeICD-10
    H35.50Unspecified hereditary retinal dystrophy
    H35.52Pigmentary retinal dystrophy
    H35.54Dystrophies primarily involving the retinal pigment epithelium
    Posterior-Pole Retinal Thickness
    Required thickness> 100 µm
    Measurement methodOptical coherence tomography (OCT)
    Measured areaAn area of retina within the posterior pole
    Patient Age
    Minimum patient ageGreater than 12 months
    Eligibility conditionThe patient must be older than 12 months at the time of treatment authorization
    Age exclusion

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Luxturna. The request must establish every applicable coverage criterion before approval.

    Documentation Required

    Diagnosis and Genetic Testing

    Submit documentation of a confirmed biallelic RPE65 mutation-associated retinal dystrophy and supporting genetic testing documenting biallelic RPE65 gene mutations.

    • Examples include Leber's congenital amaurosis (LCA), retinitis pigmentosa (RP), and early-onset severe retinal dystrophy (EOSRD).
    Documentation Required

    Document Retinal Viability by OCT

    Clinical Background

    Inherited retinal dystrophies are rare, genetically heterogeneous disorders that can cause progressive vision loss and blindness. Biallelic RPE65 mutations impair production of an enzyme required for the visual cycle and may cause Leber congenital amaurosis, retinitis pigmentosa, or other severe early-onset retinal dystrophies. Luxturna is a gene therapy that delivers a functional RPE65 gene to retinal pigment epithelial cells; treatment requires sufficient viable retinal cells.

    Clinical Definitions

    Biallelic RPE65 Mutation-Associated Retinal Dystrophy
    DefinitionAn inherited retinal dystrophy caused by pathogenic mutations in both copies of the RPE65 gene
    ExamplesLeber congenital amaurosis, retinitis pigmentosa, and early-onset severe retinal dystrophy
    Clinical effectThe disease is associated with impaired retinal function, progressive vision loss, and eventual blindness
    Sufficient Viable Retinal Cells
    DefinitionAn area of retina within the posterior pole with thickness greater than 100 µm
    Assessment methodOptical coherence tomography (OCT)
    Clinical significance

    Initial Therapy Criteria

    Initial therapy criteria

    Initial treatment is covered when all criteria are satisfied:

    • Patient and disease criteria

      • Age: Patient is greater than 12 months of age.> 12 months
      • Diagnosis: Patient has a confirmed biallelic RPE65 mutation-associated retinal dystrophy, such as Leber congenital amaurosis, retinitis pigmentosa, or early-onset severe retinal dystrophy.
      • Genetic confirmation: Genetic testing documents biallelic mutations of the RPE65 gene.Biallelic RPE65 mutations

    Quantity and Duration Limits

    Luxturna Treatment Frequency
    DrugLuxturna (voretigene neparvovec)
    Maximum frequencyNo more than one treatment per lifetime per eye
    Prior-treatment requirementThe intended eye must not have previously received Luxturna treatment
    Luxturna Authorization Duration
    DrugLuxturna (voretigene neparvovec)
    Maximum authorization durationNo longer than 45 days from approval
    Limit consequenceAuthorization may be denied or limited when the requested period exceeds 45 days

    Site of Care and Administration

    Billing Rule

    Use an eligible site of care

    Luxturna must be administered by an ophthalmologist or retinal surgeon with experience providing subretinal injections. A planned inpatient admission requested solely for administration of Luxturna is not permitted under the coverage criteria.

    Policy Summary
    PayerUnitedHealthcare
    PolicyLuxturna (Voretigene Neparvovec-Rzyl)
    Policy CodePolicy CS2026D0064Q
    Change TypeSupporting-information update
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization establishing every applicable Luxturna coverage criterion.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersProvider Actions and DocumentationClinical BackgroundClinical DefinitionsInitial Therapy CriteriaQuantity and Duration LimitsSite of Care and Administration
    Patients 12 months of age or younger do not meet this criterion
    Treatment Frequency
    Maximum treatment frequencyNo more than one treatment per lifetime per eye
    Limit applies toEach treatment eye
    Prior treatment restrictionThe intended eye must not have previously received Luxturna treatment
    Authorization Duration
    Maximum authorization periodNo longer than 45 days from approval
    Authorization basisThe authorization must comply with the policy’s treatment and authorization limits
    Exceeding the limitRequests for authorization longer than 45 days may be denied or limited

    Provide optical coherence tomography (OCT) documentation confirming sufficient viable retinal cells, including an area of retina within the posterior pole measuring > 100 µm in thickness.

    • OCT findings must support the required posterior-pole retinal thickness.
    Documentation Required

    Qualified Treating Provider and Treatment Eye

    Document that Luxturna is prescribed and administered by an ophthalmologist or retinal surgeon with experience providing sub-retinal injections, and identify the intended treatment eye.

    • The intended eye must be specified because treatment is limited per eye and prior treatment in that eye is disqualifying.
    Denial Risk

    Disease, Age, or Retinal Viability Criteria Not Met

    Coverage may be denied when the patient does not meet the disease, age, or retinal-viability requirements.

    • Patient must be greater than 12 months of age.
    • Diagnosis must be confirmed biallelic RPE65 mutation-associated retinal dystrophy.
    • OCT must confirm sufficient viable retinal cells, including a posterior-pole area with thickness > 100 µm.
    Denial Risk

    Provider, Prior-Treatment, or Setting Criteria Not Met

    Coverage may be denied when provider, prior-treatment, or treatment-setting requirements are not met.

    • Treatment must be prescribed and administered by an ophthalmologist or retinal surgeon experienced in sub-retinal injections.
    • The patient must not have previously received Luxturna treatment in the intended eye.
    • A planned inpatient admission may not be requested solely to administer Luxturna.
    Denial Risk

    Lifetime and Authorization-Duration Limits

    Authorization is limited to one treatment per lifetime per eye and will be issued for no longer than 45 days from approval.

    • Requests exceeding the lifetime treatment frequency or 45-day authorization-duration limit may be denied or limited.
    Note

    State-Specific Policy Exclusions

    This policy does not apply in the listed states. Use the applicable state-specific Medicaid policy, guideline, or manual where directed.

    • Florida: Refer to the state's Medicaid clinical policy.
    • Indiana: Source lists no state-specific policy/guideline ("None").
    • Kansas: Refer to the state's Medicaid clinical policy.
    • Ohio: Use the Luxturna (voretigene neparvovec-rzyl) policy for Ohio only.
    • Texas: Refer to drug-specific criteria in the Texas Medicaid Provider Procedures Manual.
    • Virginia: Refer to the state's Medicaid clinical policy.
    The finding indicates sufficient viable retinal cells for treatment
  1. Retinal viability: Optical coherence tomography confirms sufficient viable retinal cells, defined as an area of retina within the posterior pole with thickness greater than 100 µm.> 100 µm posterior-pole thickness
  2. Administration and authorization criteria

    • Qualified provider: Luxturna is prescribed and administered by an ophthalmologist or retinal surgeon with experience providing subretinal injections.
    • No prior treatment in intended eye: The patient has not previously received Luxturna treatment in the intended eye.
    • Inpatient admission restriction: The provider does not request a planned inpatient admission for the sole purpose of administering Luxturna.
    • Treatment and authorization limits: Authorization is requested for no more than one treatment per lifetime per eye and for no longer than 45 days from approval.1 treatment per lifetime per eye; authorization no longer than 45 days